Abstract
The histological classification of breast tumors by the General Rule Committee of the Japanese Breast Cancer Society has been revised in the General Rules for Clinical and Pathological Recording of Breast Cancer (18th edition). In this article, the contents of the General Rules 18th edition are presented, and its revised points are briefly described in comparison with the classification of the General Rules 17th edition. The present classification takes into consideration the classification of breast tumors by the World Health Organization 4th edition, however, some differences remain. These differences will be briefly mentioned.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Change history
19 May 2020
In the original publication of the article, the author group and acknowledgements were published incorrectly.
References
Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer. 18th ed. Tokyo: Kanehara Shuppan; 2018. p. 23–67.
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, editors. WHO classification of tumours of the breast. 4th ed. Lyon: International Agency for Research on Cancer; 2012.
Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer. 17th ed. Tokyo: Kanehara Shuppan; 2012. p. 22–34.
Japanese Orthopaedic Association Committee of Tumors. General rules for clinical and pathological studies on malignant soft tissue tumor. 4th ed. Tokyo: Kanehara Shuppan; 2015.
Acknowledgements
The authors greatly thanks to Dr. Shu Ichihara, Department of Pathology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan, for intensive and instructing discussion as a working group member for histological classification. The members of General Rule Committee of the Japanese Breast Cancer Society are: Koichiro Tsugawa: Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan; Futoshi Akiyama: Division of Pathology, Clinicopathology Center, The Cancer Institute of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan; Rie Horii: Department of Pathology, Saitama Cancer Center, 780 Komuro, Ina-machi, Kita-adachi-gun, Saitama 362-0806, Japan; Masafumi Kurosumi: Division of Pathology, Breast Center, Kameda Medical Center, Tokyo Square Garden, 3-1-1 Kyobashi, Chuo-ku, Tokyo 104-0031, Japan; Takuya Moriya: Department of Pathology, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701-0192, Japan; Toshimi Takano: Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan; Hiroyuki Takei: Graduate School and Department of Breast Surgery and Oncology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan; Takahiro Nakayama: Department of Breast and Endocrine Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka 541-8567, Japan; Yumi Miyagi: Department of Breast Surgery, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan; Chikako Yamauchi: Department of Radiation Oncology, Shiga General Hospital, 5-4-30 Moriyama, Moriyama-shi, Shiga 524-8524, Japan; Toshinari Yamashita: Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-0815, Japan; Kenjiro Aogi: Division of Clinical Research Promotion, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minami-umemoto-machi, Matsuyama, Ehime 791-0280, Japan; Hirofumi Mukai: Department of Breast and Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan; Tomoharu Sugie: Breast Surgery, Kansai Medical University Hospital, 2-3-1 Shinmachi, Hirakata, Osaka 573-1191, Japan; Hiroji Iwata: Department of Breast Oncology, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan; Shinobu Masuda: Division of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, 30-1 Oyaguchi Kami-cho, Itabashi-ku, Tokyo 173-8610, Japan.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
H. Tsuda reports grants from Chugai and Taiho, personal fees from Roche Diagnostics, Konica Minolta, Eisai, AstraZeneca, and Bristol-Meyers Squibb, outside the submitted work. F. Akiyama reports grants and personal fees from Sysmex and perfomal fees from Taiho, AstraZeneca, Chugai, Pfizer, Century Medical, Bayer, Nihon Kayaku, Eisai, Medicon, Kyowa Hakko Kirin and GE Healthcare, outside the submitted work. R. Horii reports personal fees from Chugai, Roche Diagnostics, Pfizer, Takeda, Taiho, and US lead, outside the submitted work. M. Kurosumi reports personal fees from Chugai and Taiho outside the submitted work. T. Takano reports grants and personal fees from Daiichi-Sankyo, Kyowa Kirin and Eisai, grants from Ono, MSD, Merck Serono, Taiho, Novartis, and Chugai, personal fees from Pfizer and Eli Lilly, outside the submitted work. T. Nakayama reports remuneration from Chugai, AstraZeneca, Pfizer, Eli Lilly, Takeda, Taiho, Eisai, Daiichi Sankyo and Novartis outside the submitted work. T. Yamashita reports grants and other from Chugai, Taiho, Kyowa Kirin, and Nippon Kayaku, other from Eisai, Novartis Pharma, AstraZeneca, Pfizer Japan, and Eli Lilly, outside the submitted work. H. Mukai received honoraria from AstraZeneca, Pfizer, Takeda, Daiichi Sankyo and Taiho and research grants from Japanese government, Daiichi Sankyo, Eisai, Nippon Kayaku and Pfizer, outside the submitted work. H. Iwata reports grants and personal fees from Novartis, AstraZeneca, Pfizer, Eli Lilly, Daiichi-Sankyo, Kyowa Hakko Kirin, and Chugai, grants from MSD and Byer, and personal fees from Eisai, outside the submitted work. K. Tsugawa, T. Moriya, H. Takei, Y. Miyagi, C. Yamauchi, K. Aogi, T. Sugie, and S. Masuda have nothing to disclose.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The members of General Rule Committee of the Japanese Breast Cancer Society are listed in “Acknowledgements”.
About this article
Cite this article
Tsuda, H., General Rule Committee of the Japanese Breast Cancer Society. Histological classification of breast tumors in the General Rules for Clinical and Pathological Recording of Breast Cancer (18th edition). Breast Cancer 27, 309–321 (2020). https://doi.org/10.1007/s12282-020-01074-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12282-020-01074-3